Neuroprotective propensity of PTUPB, a dual inhibitor of sEH and COX-2 against rotenone induced neurotoxicity in cell line and Drosophila model of Parkinson disease
Objective: To evaluate the potential anti-parkinson activity of PTUPB (4-(5-phenyl-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide) a dual inhibitor of soluble Epoxide hydrolase (sEH) and cyclooxygenase-2 (COX-2) against rotenone induced mitochondrial dysfunction,…Prevalence of Babinski-2 sign in Hemifacial Spasm Patients
Objective: To assess the frequency of Babinski-2 sign among patients with hemifacial spasm (HFS). Background: The Babinski-2 sign (“the other” Babinski sign, “brow-lift sign”), is…Some clincal features of movement disorders after cerebral anoxia.
Objective: To describe some clinical features of movement disorders after cerebral anoxia. Background: The basal ganglia, especially the globi pallidi (GP), are highly vulnerable to…The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Effect Of Non-Invasive Vagus Nerve Stimulation In Freezing And Oxidative Stress In Parkinson’s Disease Patients
Objective: In this observational pilot study we explored the long term effect of Non-Invasive VNS to improve the FOG and reduce oxidative stress in PD…Improving Racial and Ethnic Diversity in Parkinson`s Disease Clinical Trials
Objective: To identify and overcome challenges to recruiting minorities in Parkinson's Disease experimental therapeutic trials. Background: Inadequate representation of ethnic and minority population poses substantial…ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
Objective: Characterize the levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612. Background: Continuous levodopa/carbidopa (LD/CD) infusion is considered the optimal delivery route…The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily to slow progression of disability in early PD. Background: Isradipine, a dihydropyridine calcium channel antagonist,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.